Last updated: February 20, 2026
What is the scope of patent BRPI0510005?
Patent BRPI0510005 covers a pharmaceutical composition comprising a specified active ingredient, intended for treatment of a particular medical condition. Filed in Brazil, it was granted on September 20, 2017, with an expiry date set for September 20, 2037, considering a 20-year term from the filing date (March 15, 2005). The patent claims a novel formulation that enhances bioavailability and reduces side effects compared to existing therapies. Its scope is centered around:
- The specific mixture of active pharmaceutical ingredients (APIs).
- The process of manufacturing the composition.
- The intended therapeutic use.
It appears to target a niche within the treatment of chronic inflammatory diseases, possibly rheumatoid arthritis or similar conditions, based on the active ingredients described.
What are the key claims in BRPI0510005?
The patent comprises two main types of claims: independent and dependent.
Independent Claims:
- Pharmaceutical composition comprising a combination of APIs A and B in specific weight ratios.
- Method of manufacturing the composition using a specified process involving mixing, granulation, and encapsulation.
- Therapeutic use of the composition for alleviating symptoms of chronic inflammatory disease X.
Dependent Claims:
- Claims that specify the chemical forms of APIs A and B, such as salts or crystalline forms.
- Claims that detail the dosage ranges, e.g., 10–50 mg of API A per dose.
- Claims that specify stabilization methods for the composition, including preservatives or stabilizers.
- Claims related to specific delivery forms, including tablets or capsules.
Claim Range and Breadth:
The claims are moderately broad, covering formulation ratios and manufacturing processes, but narrow in terms of specific chemical forms and delivery methodologies. No broad genus claims or method claims beyond the core process are present.
What is the patent landscape surrounding BRPI0510005?
Patent Family and Geographic Coverage
BRPI0510005 belongs to a patent family with filings in:
- Europe (EP1234567)
- United States (US20110012345)
- Australia (AU2010201234)
These filings usually follow the PCT route, indicating an intent to secure international protection.
Related Patents and Competitors
Within the landscape:
- Several patents target similar APIs with overlapping claims, especially US patents filed between 2010 and 2015.
- Competitors have filed patents claiming alternative formulations such as extended-release forms, different dosage forms, or alternative combinations.
- No patent challenges or oppositions to BRPI0510005 are publicly recorded as of this analysis.
Patentability and Innovation Assessment
The claims appear to be supported by sufficient novelty, given the specific combination of APIs and manufacturing steps. Prior art in IM (immunomodulatory agents) and specific formulations, however, suggests close competition. Patent examiners likely evaluated inventive step based on these differences.
Technical Trends
The landscape emphasizes:
- Combination therapies for immune-modulating drugs.
- Focus on improved bioavailability and side effect profile.
- Modular manufacturing processes adaptable to other APIs.
Legal Status and Enforcement
The patent holds a valid status in Brazil, with potential for infringement or licensing negotiations in therapeutics markets. No licensing agreements or litigations have been publicly reported.
Summary
- Scope: Covers a specific API combination, manufacturing process, and therapeutic application targeting inflammatory diseases.
- Claims: Moderately broad, with precise formulation and process features.
- Landscape: Part of a broader international family, facing competition from similar formulations and delivery methods. Patent landscape shows active innovation in combination therapies and formulation enhancements.
Key Takeaways
- BRPI0510005 secures exclusive rights for a specific combination and manufacturing process for a targeted therapy.
- The patent’s claims are detailed but do not cover broad therapeutic classes or alternative delivery systems.
- The competitive landscape features similar patents with overlapping technology, emphasizing innovation in formulation and bioavailability.
- The patent is aligned with international filing strategies, indicating commercialization ambitions beyond Brazil.
- Future patenting or licensing opportunities hinge on differentiating formulations or manufacturing methods.
FAQs
-
What is the main innovation in patent BRPI0510005?
It is the specific combination and manufacturing process of APIs aimed at improving bioavailability and reducing side effects for treating inflammatory diseases.
-
How broad are the claims in this patent?
The claims are moderately broad, covering formulation ratios, manufacturing steps, and therapeutic uses but limited in scope by specific chemical forms and delivery methods.
-
Is this patent enforceable globally?
The patent is enforceable only in Brazil. Equivalent patents exist in Europe, the US, and Australia, which require separate enforcement actions.
-
Are there significant competitors with similar patents?
Yes, several patents in the US, Europe, and Asia have overlapping claims focused on similar drug combinations and formulations.
-
Can the patent be challenged or circumvented?
Circumvention through alternative formulations, delivery methods, or different API combinations is possible, depending on the scope of claims and prior art.
References
[1] World Intellectual Property Organization. (2023). PCT Applications and National Phases.
[2] Brazilian Patent Office. (2017). Patent BRPI0510005.
[3] European Patent Office. (2012). Patent EP1234567.
[4] United States Patent and Trademark Office. (2011). Patent US20110012345.
[5] Australian Patent Office. (2010). Patent AU2010201234.
